These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Sijpkens YW; Joosten SA; Wong MC; Dekker FW; Benediktsson H; Bajema IM; Bruijn JA; Paul LC Kidney Int; 2004 Jun; 65(6):2409-18. PubMed ID: 15149354 [TBL] [Abstract][Full Text] [Related]
4. Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival. Aubert O; Higgins S; Bouatou Y; Yoo D; Raynaud M; Viglietti D; Rabant M; Hidalgo L; Glotz D; Legendre C; Delahousse M; Shah N; Sis B; Campbell P; Mengel M; Jouven X; Duong Van Huyen JP; Lefaucheur C; Loupy A J Am Soc Nephrol; 2019 Apr; 30(4):625-639. PubMed ID: 30872323 [TBL] [Abstract][Full Text] [Related]
5. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection. Torres IB; Salcedo M; Moreso F; Sellarés J; Castellá E; Azancot MA; Perelló M; Cantarell C; Serón D Clin Transplant; 2014 Oct; 28(10):1148-54. PubMed ID: 25103874 [TBL] [Abstract][Full Text] [Related]
6. Molecular signatures and clinical outcomes of transplant glomerulopathy stratified by microvascular inflammation and donor-specific antibody. Lubetzky M; Hayde N; Ó Broin P; Ajaimy M; Bao Y; Mohammed O; Schwartz D; Pullman J; Akalin E Clin Transplant; 2019 Mar; 33(3):e13469. PubMed ID: 30578675 [TBL] [Abstract][Full Text] [Related]
7. Impact of HLA antibodies on transplant glomerulopathy. Palomar R; López-Hoyos M; Pastor JM; Fernández-Fresnedo G; Rodrigo E; Ruiz JC; Cotorruelo JG; Valero R; Castañeda O; San Segundo D; Arias M Transplant Proc; 2005 Nov; 37(9):3830-2. PubMed ID: 16386554 [TBL] [Abstract][Full Text] [Related]
8. Histopathologic Features that Predict Transplant Glomerulopathy Progression in a Chinese Cohort. Li X; Chen J; Cheng D; Wang W; Xie K; Zhang M; Xu F; Wen J; Tang Z Am J Nephrol; 2019; 49(6):425-434. PubMed ID: 30991390 [TBL] [Abstract][Full Text] [Related]
9. Kidney allograft failure in the steroid-free immunosuppression era: A matched case-control study. Alkadi MM; Kim J; Aull MJ; Schwartz JE; Lee JR; Watkins A; Lee JB; Dadhania DM; Seshan SV; Serur D; Kapur S; Suthanthiran M; Hartono C; Muthukumar T Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28921709 [TBL] [Abstract][Full Text] [Related]
10. The clinical and pathological significance of borderline T cell-mediated rejection. Nankivell BJ; Agrawal N; Sharma A; Taverniti A; P'Ng CH; Shingde M; Wong G; Chapman JR Am J Transplant; 2019 May; 19(5):1452-1463. PubMed ID: 30501008 [TBL] [Abstract][Full Text] [Related]
11. Interstitial fibrosis is the critical determinant of impaired renal function in transplant glomerulopathy. Toki D; Inui M; Ishida H; Okumi M; Shimizu T; Shirakawa H; Omoto K; Unagami K; Setoguchi K; Koike J; Honda K; Yamaguchi Y; Tanabe K Nephrology (Carlton); 2016 Jul; 21 Suppl 1():20-5. PubMed ID: 26970313 [TBL] [Abstract][Full Text] [Related]
12. Older kidney transplant patients experience less antibody-mediated rejection: a retrospective study of patients with mild to moderate sensitization. Scalea JR; Redfield RR; Muth BL; Mohamed M; Wilson NA; Ellis TM; Kaufman DB; Djamali A Clin Transplant; 2015 Dec; 29(12):1090-7. PubMed ID: 26361077 [TBL] [Abstract][Full Text] [Related]
13. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Issa N; Cosio FG; Gloor JM; Sethi S; Dean PG; Moore SB; DeGoey S; Stegall MD Transplantation; 2008 Sep; 86(5):681-5. PubMed ID: 18791449 [TBL] [Abstract][Full Text] [Related]
15. Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation. Orandi BJ; Alachkar N; Kraus ES; Naqvi F; Lonze BE; Lees L; Van Arendonk KJ; Wickliffe C; Bagnasco SM; Zachary AA; Segev DL; Montgomery RA Am J Transplant; 2016 Jan; 16(1):213-20. PubMed ID: 26317487 [TBL] [Abstract][Full Text] [Related]
16. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748 [TBL] [Abstract][Full Text] [Related]
18. Three-year outcome of isolated glomerulitis on 3-month protocol biopsies of donor HLA antibody negative patients. Buob D; Grimbert P; Glowacki F; Labalette M; Dufossé F; Nochy D; Copin MC; Boleslawski E; Noël C; Hazzan M Transpl Int; 2012 Jun; 25(6):663-70. PubMed ID: 22487459 [TBL] [Abstract][Full Text] [Related]
19. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738 [TBL] [Abstract][Full Text] [Related]
20. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Kahwaji J; Najjar R; Kancherla D; Villicana R; Peng A; Jordan S; Vo A; Haas M Clin Transplant; 2014 May; 28(5):546-53. PubMed ID: 24579925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]